Coronary artery disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 1
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TP53 0
• HMGB1 0
• STAT3 0
• TLR4 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Netherlands· EU contribution €2,500,000· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,499,585· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Lithuania· EU contribution €196,976· until Jan 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Malta· EU contribution €205,314· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 72 running projects, newest first. Listed amounts together: €236.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Source

• The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

  NCT06606821· Tina Vilsbøll· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 161
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

• dioscRi enables transferable prediction of clinical outcomes in multi-parameter cytometry data.

  Nat Commun, Aug 2026

• Whole Blood Flow Cytometric Quantification of Tissue Factor-Positive Platelets: A Harmonized Multicenter Workflow.

  J Vis Exp, Aug 2026

• Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.

  Catheter Cardiovasc Interv, Jun 2026

• Reduction in circulating endothelial progenitor cells caused by obstructive sleep apnea-related hypoxemia and its association with the severity of coronary artery disease.

  Coron Artery Dis, Jan 2026

• Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease.

  Bull Exp Biol Med, Jun 2017

• Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.

  Oncotarget, Mar 2017

• Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation.

  Int Immunopharmacol, Mar 2015

• The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.

  J Am Coll Cardiol, Jan 2015

• Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.

  Braz J Med Biol Res, May 2014

• Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model.

  Isr Med Assoc J, Nov 2013

See which targets of this disease your abstract mentions, and go to the people working on them.